Antibe receives OK for ATB-346 phase 2 trial

2016-03-04 15:15 ET - News Release

Mr. Dan Legault reports
ANTIBE THERAPEUTICS RECEIVES APPROVAL TO PROCEED TO PHASE 2 CLINICAL TRIAL

Antibe Therapeutics Inc. has received approval from Health Canada to initiate a phase 2 trial. Antibe submitted an application to Health Canada to perform a trial in which ATB-346, its lead drug, would be tested for effectiveness in patients with osteoarthritis of the knee. The study is expected to begin in March and will be performed by Topstone Research in Toronto. Antibe's chief executive officer, Daniel Legault, commented: "We are delighted to move forward into patients. In the past year, we have performed a number of non-clinical studies of this drug, and these studies suggest that ATB-346 is a much more potent and long-lasting anti-inflammatory drug than we had anticipated."
We seek Safe Harbor.